Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 59%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Natera is expected to see revenue growth from their successful MRD testing, expansion into different clinical areas, and potential FDA approvals, cementing its leadership in the MRD monitoring market and justifying a high valuation and stock price target of $275, although market penetration stagnation remains a risk.

Bears say

Natera is facing competition from other labs and may face challenges in entering new markets, which could impact its revenue and profitability. Additionally, securing FDA approval for precision oncology tests has become increasingly important, and Natera may face challenges in meeting this requirement. Furthermore, there is potential for downside risk due to increasing competition in the emerging MRD landscape and persistent competitive intensity in the Women's Health market. This could impact Natera's ability to achieve its goal of reaching an ASP of $2,000 for its Signatera test.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 59% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $263.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $263.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.